Markers for individualised therapy in endometrial carcinoma (Q38030768)

27 August 2017

Markers for individualised therapy in endometrial carcinoma (English)

1 reference

27 August 2017

2

1 reference

27 August 2017

3

Jone Trovik

1 reference

27 August 2017

1

Helga B Salvesen

1 reference

27 August 2017

1 August 2012

1 reference

Lancet Oncology Commission

27 August 2017

1 reference

27 August 2017

13

1 reference

27 August 2017

8

1 reference

27 August 2017

e353-61

1 reference

27 August 2017

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

1 reference

7 January 2021

Endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Adjuvant chemotherapy for endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Emerging therapeutic targets in endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Two pathogenetic types of endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Clinical factors affecting the diagnostic accuracy of assessing dilation and curettage vs frozen section specimens for histologic grade and depth of myometrial invasion in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Concordance of FIGO grade of endometrial adenocarcinomas in biopsy and hysterectomy specimens

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

MRI of malignant neoplasms of the uterine corpus and cervix.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Staging of endometrial cancer with MRI: guidelines of the European Society of Urogenital Imaging.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

PET and PET-CT imaging of gynecological malignancies: present role and future promise

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Staging of endometrial carcinomas with MRI using traditional and novel MRI techniques

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Preoperative local staging of endometrial cancer: transvaginal sonography vs. magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Standard 1.5-T MRI of endometrial carcinomas: modest agreement between radiologists.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Three-dimensional ultrasound for assessing women with gynecological cancer: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Detection of lymph node metastasis in cervical and uterine cancers by diffusion-weighted magnetic resonance imaging at 3T

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Magnetic resonance lymphography: a novel technique for lymph node assessment in gynecologic malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Comparative performance of the 2009 international Federation of gynecology and obstetrics' staging system for uterine corpus cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Revision of FIGO surgical staging in 2009 for endometrial cancer validates to improve risk stratification

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

The current status of lymphadenectomy in the management of endometrial cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Influence of gynecologic oncologists on the survival of patients with endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Lymphadenectomy influences the utilization of adjuvant radiation treatment for endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Improved survival related to changes in endometrial cancer treatment, a 30-year population based perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

A binary architectural grading system for uterine endometrial endometrioid carcinoma has superior reproducibility compared with FIGO grading and identifies subsets of advance-stage tumors with favorable and unfavorable prognosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Significant variation in the assessment of cervical involvement in endometrial carcinoma: an interobserver variation study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Clinical significance of microsatellite instability in endometrial carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Abnormalities of E- and P-cadherin and catenin (β-, γ-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Drug-sensitive FGFR2 mutations in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Prognostic importance of DNA ploidy and DNA index in stage I and II endometrioid adenocarcinoma of the endometrium

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Pretreatment assessment of prognostic indicators in endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Deoxyribonucleic acid ploidy in endometrial carcinoma: a reproducible and valid prognostic marker in a routine diagnostic setting

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Prognostic significance of hormone receptors in endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Flow cytometric deoxyribonucleic acid index: a prognostic factor in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Ten-year results of a prospective study on the prognostic role of ploidy in endometrial carcinoma: dNA aneuploidy identifies high-risk cases among the so-called 'low-risk' patients with well and moderately differentiated tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Prognostic impact of histological grade and vascular invasion compared with tumour cell proliferation in endometrial carcinoma of endometrioid type.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Her-2/neu overexpression and amplification in uterine papillary serous carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Elevated plasma growth differentiation factor-15 correlates with lymph node metastases and poor survival in endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

Stratification based on high tumour cell content in fresh frozen tissue promotes selection of aggressive endometrial carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970213-9

7 January 2021

10.1016/S1470-2045(12)70213-9

Identifiers

DOI

1 reference

PubMed ID

22846840

OpenCitations bibliographic resource ID

27 August 2017

0 references

1 reference

PubMed ID

22846840